InvestorsObserver
×
News Home

Should You Accumulate Novartis AG (NVS) in Drug Manufacturers - General Industry?

Thursday, April 15, 2021 01:11 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Accumulate Novartis AG (NVS) in Drug Manufacturers - General Industry?

A rating of 63 puts Novartis AG (NVS) near the middle of the Drug Manufacturers - General industry according to InvestorsObserver. Novartis AG's score of 63 means it scores higher than 63% of stocks in the industry. Novartis AG also received an overall rating of 38, putting it above 38% of all stocks. Drug Manufacturers - General is ranked 135 out of the 148 industries.

Overall Score - 38
NVS has an Overall Score of 38. Find out what this means to you and get the rest of the rankings on NVS!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Novartis AG Stock Today?

Novartis AG (NVS) stock is trading at $87.42 as of 1:02 PM on Thursday, Apr 15, a rise of $0.67, or 0.77% from the previous closing price of $86.76. Volume today is 1,387,892 compared to average volume of 1,771,533. The stock has traded between $86.82 and $87.83 so far today.

Click Here to get the full Stock Score Report on Novartis AG (NVS) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App